long-term follow-up prognost factor analysi advanc ovarian carcinoma gynecolog oncolog group experi long-term follow-up women advanc ovarian carcinoma suboptim stage iii IV primari chemotherapi gynecolog oncolog group gog first studi melphalan versu melphalan hexamethylmelamin versu cyclophosphamid doxorubicin CA second studi CA regimen cisplatin elig studi last contact patient aliv multivari analysi cell type clear cell mucin cisplatin-bas treatment good perform statu age stage nonmeasur diseas residu tumor volum absenc ascit favor characterist overal surviv second-look laparotomi neg endometrioid tumor neg second-look laparotomi mucin clear cell tumor patient suboptim stage iii diseas neg second-look laparotomi recurr cisplatin treatment benefici new treatment 